Programming of cells for tolerogenic therapies
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-039/35
A61K-039/39
A61K-039/102
출원번호
US-0147442
(2016-05-05)
등록번호
US-10080789
(2018-09-25)
발명자
/ 주소
Sands, Roger Warren
Barros E Silva, Eduardo Alexandre
Kawai, Toshihisa
Mooney, David J.
출원인 / 주소
President and Fellows of Harvard College
대리인 / 주소
McCarter & English, LLP
인용정보
피인용 횟수 :
0인용 특허 :
40
초록▼
Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, all
Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.
대표청구항▼
1. A scaffold composition comprising an antigen, a recruitment composition, and a tolerogen, wherein said antigen is derived from a cell to which a pathologic autoimmune response associated with an autoimmune disorder is directed;wherein said tolerogen induces immune tolerance or a reduction in an i
1. A scaffold composition comprising an antigen, a recruitment composition, and a tolerogen, wherein said antigen is derived from a cell to which a pathologic autoimmune response associated with an autoimmune disorder is directed;wherein said tolerogen induces immune tolerance or a reduction in an immune response;wherein said tolerogen is selected from the group consisting of thymic stromal lymphopoietin, retinoic acid, rapamycin, aspirin, and vasoactive intestinal peptide; andwherein the scaffold composition does not comprise IL-10, dexamethasone, vitamin D, or transforming growth factor-beta (TGF-β). 2. The composition of claim 1, wherein said autoimmune disorder is type 1 diabetes. 3. The composition of claim 1, wherein said antigen comprises a pancreatic cell antigen. 4. The composition of claim 3, wherein said antigen comprises insulin, proinsulin, glutamic acid decarboxylase-65 (GAD65), insulinoma-associated protein 2, heat shock protein 60, ZnT8, or islet-specific glucose-6-phosphatase catalytic subunit. 5. The composition of claim 1, wherein said autoimmune disorder is multiple sclerosis. 6. The composition of claim 5, wherein said antigen comprises myelin basic protein, myelin proteolipid protein, myelin-associated oligodendrocyte basic protein, or myelin oligodendrocyte glycoprotein. 7. The composition of claim 1, wherein said recruitment composition comprises GM-CSF, FMS-like tyrosine kinase 3 ligand, N-formyl peptides, fractalkine, or monocyte chemotactic protein-1. 8. The composition of claim 7, wherein said recruitment composition comprises GM-CSF. 9. The composition of claim 1, comprising a non-inflammatory polymer. 10. The composition of claim 9, wherein said non-inflammatory polymer comprises alginate, poly(ethylene glycol), hyaluronic acid, collagen, gelatin, poly(vinyl alcohol), fibrin, poly(glutamic acid), peptide amphiphiles, silk, fibronectin, chitin, poly(methyl methacrylate), poly(ethylene terephthalate), poly(dimethylsiloxane), poly(tetrafluoroethylene), polyethylene, polyurethane, poly(glycolic acid), poly(lactic acid), poly(caprolactone), poly(lactide-co-glycolide) (PLGA), polydioxanone, polyglyconate, BAK; poly(ortho ester I), poly(ortho ester) II, poly(ortho ester) III, poly(ortho ester) IV, polypropylene fumarate, poly[(carboxy phenoxy)propane-sebacic acid], poly[pyromellitylimidoalanine-co-1,6-bis(p-carboxy phenoxy)hexane], polyphosphazene, starch, cellulose, albumin, polyhydroxyalkanoates, poly(lactide), or poly(glycolide). 11. The composition of claim 1, comprising a hydrogel. 12. The composition of claim 11, wherein said hydrogel comprises an alginate gel polymer. 13. The composition of claim 12, wherein said hydrogel comprises 1-5% alginate gel polymer. 14. The composition of claim 13, wherein said alginate gel polymer is crosslinked. 15. The composition of claim 1, wherein the tolerogen is encapsulated in poly(lactide-co-glycolide) (PLGA) microspheres. 16. The composition of claim 1, which is suitable for administration by injection, implantation, topically affixing a skin patch comprising the scaffold composition, or aerosol delivery into a lung or nasal passage of the subject. 17. The composition of claim 16, which is suitable for administration by intradermal implantation. 18. The composition of claim 1, wherein said autoimmune disorder is Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus, Scleroderma, Alopecia areata, Antiphospholipid antibody syndrome, Autoimmune hepatitis, Celiac disease, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, Hemolytic anemia, Idiopathic thrombocytopenic purpura, inflammatory bowel disease, ulcerative colitis, inflammatory myopathies, Polymyositis, Myasthenia gravis, Primary biliary cirrhosis, Psoriasis, Sjogren's syndrome, Vitiligo, gout, celiac disease, atopic dermatitis, acne vulgaris, autoimmune hepatitis, or autoimmune pancreatitis. 19. The composition of claim 1, comprising 0.1 μg to 10 μg of said tolerogen. 20. The composition of claim 1, comprising 0.1 μg to 10 μg of said recruitment composition. 21. The composition of claim 1, comprising an alginate gel and granulocyte macrophage colony-stimulating factor (GM-CSF).
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (40)
Huston James S. (Chestnut Hill MA) Oppermann Hermann (Medway MA), Biosynthetic antibody binding sites.
Pardoll Drew ; Azhari Rosa,ILX ; Leong Kam W. ; Golumbe Paul K ; Jaffee Elizabeth ; Levitsky Hyam ; Lazenby Audrey, Controlled release of pharmaceutically active substances for immunotherapy.
Gaur Amitabh ; Conlon Paul ; Ling Nicholas C. ; Staehelin Theophil,CHX ; Crowe Paul D., Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
Murphy, William L.; Mooney, David J.; Kohn, David H.; Spalding, Gabriel C.; Dearing, Matthew T., Mineral and cellular patterning on biomaterial surfaces.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
Hackam, David J.; Gribar, Steven C., Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.